Anne-Sophie Brazeau

Prof. Anne-Sophie Brazeau

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2015 in BMC Public Health
Verified
Journal Article
Open access
PDF file
SHSamantha Hajna
Samantha Hajna
NRNancy Ross
Nancy Ross
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau
PBPatrick Bélisle
Patrick Bélisle
LJLawrence Joseph
Lawrence Joseph
KDKaberi Dasgupta
Kaberi Dasgupta
Higher street connectivity, land use mix and residential density (collectively referred to as neighbourhood walkability) have been linked to higher levels of walking. The objective of our study was to summarize the current body of knowledge on the association between neighbourhood walkability and biosensor-assessed daily steps in adults. We conducted a systematic search of PubMed, SCOPUS, and Embase (Ovid) for articles published prior to May 2014 on the association between walkability (based on Geographic Information Systems-derived street connectivity, land use mix, and/or residential density) and daily steps (pedometer or accelerometer-assessed) in adults. The mean differences in daily steps between adults living in high versus low walkable neighbourhoods were pooled across studies using a Bayesian hierarchical model. The search strategy yielded 8,744 unique abstracts. Thirty of these underwent full article review of which six met the inclusion criteria. Four of these studies were conducted in Europe and two were conducted in Asia. A meta-analysis of four of these six studies indicates that participants living in high compared to low walkable neighbourhoods accumulate 766 more steps per day (95 % credible interval 250, 1271). This accounts for approximately 8 % of recommended daily steps. The results of European and Asian studies support the hypothesis that higher neighbourhood walkability is associated with higher levels of biosensor-assessed walking in adults. More studies on this association are needed in North America.

20 April 2018 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau
MNMeranda Nakhla
Meranda Nakhla
MWMichael Wright
Michael Wright
Melanie HendersonMelanie Henderson
Melanie Henderson
CPConstadina Panagiotopoulos
Constadina Panagiotopoulos
KDKaberi Dasgupta
Kaberi Dasgupta
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

28 May 2022 in Canadian Journal of Diabetes
Verified
Journal Article
Closed access
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau
VMVirginie Messier
Virginie Messier
MTMeryem K. Talbo
Meryem K. Talbo
CGClaudia Gagnon
Claudia Gagnon
NTNadine Taleb
Nadine Taleb
RRRémi Rabasa-Lhoret
Rémi Rabasa-Lhoret

21 November 2022 in Journal of Medical Internet Research
Verified
Journal Article
Open access
AMAudrey Moyen
Audrey Moyen
ARAviva Ilysse Rappaport
Aviva Ilysse Rappaport
CFChloé Fleurent-Grégoire
Chloé Fleurent-Grégoire
ATAnne-Julie Tessier
Anne-Julie Tessier
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau
SCStephanie Chevalier
Stephanie Chevalier
Background: Thorough dietary assessment is essential to obtain accurate food and nutrient intake data yet challenging because of the limitations of current methods. Image-based methods may decrease energy underreporting and increase the validity of self-reported dietary intake. Keenoa is an image-assisted food diary that integrates artificial intelligence food recognition. We hypothesized that Keenoa is as valid for dietary assessment as the automated self-administered 24-hour recall (ASA24)–Canada and better appreciated by users. Objective: We aimed to evaluate the relative validity of Keenoa against a 24-hour validated web-based food recall platform (ASA24) in both healthy individuals and those living with diabetes. Secondary objectives were to compare the proportion of under- and overreporters between tools and to assess the user’s appreciation of the tools. Methods: We used a randomized crossover design, and participants completed 4 days of Keenoa food tracking and 4 days of ASA24 food recalls. The System Usability Scale was used to assess perceived ease of use. Differences in reported intakes were analyzed using 2-tailed paired t tests or Wilcoxon signed-rank test and deattenuated correlations by Spearman coefficient. Agreement and bias were determined using the Bland-Altman test. Weighted Cohen κ was used for cross-classification analysis. Energy underreporting was defined as a ratio of reported energy intake to estimated resting energy expenditure <0.9. Results: A total of 136 participants were included (mean 46.1, SD 14.6 years; 49/136, 36% men; 31/136, 22.8% with diabetes). The average reported energy intakes (kcal/d) were 2171 (SD 553) in men with Keenoa and 2118 (SD 566) in men with ASA24 (P=.38) and, in women, 1804 (SD 404) with Keenoa and 1784 (SD 389) with ASA24 (P=.61). The overall mean difference (kcal/d) was −32 (95% CI −97 to 33), with limits of agreement of −789 to 725, indicating acceptable agreement between tools without bias. Mean reported macronutrient, calcium, potassium, and folate intakes did not significantly differ between tools. Reported fiber and iron intakes were higher, and sodium intake lower, with Keenoa than ASA24. Intakes in all macronutrients (r=0.48-0.73) and micronutrients analyzed (r=0.40-0.74) were correlated (all P<.05) between tools. Weighted Cohen κ scores ranged from 0.30 to 0.52 (all P<.001). The underreporting rate was 8.8% (12/136) with both tools. Mean System Usability Scale scores were higher for Keenoa than ASA24 (77/100, 77% vs 53/100, 53%; P<.001); 74.8% (101/135) of participants preferred Keenoa. Conclusions: The Keenoa app showed moderate to strong relative validity against ASA24 for energy, macronutrient, and most micronutrient intakes analyzed in healthy adults and those with diabetes. Keenoa is a new, alternative tool that may facilitate the work of dietitians and nutrition researchers. The perceived ease of use may improve food-tracking adherence over longer periods.

4 August 2023 in eClinicalMedicine
Verified
Journal Article
Open access
MTMeryem K. Talbo
Meryem K. Talbo
AKAlexandra Katz
Alexandra Katz
LHLee Hill
Lee Hill
TPTricia M. Peters
Tricia M. Peters
JYJean-François Yale
Jean-François Yale
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau
Fear of hypoglycaemia (FOH) significantly disrupts the daily management of type 1 diabetes (T1D) and increases the risk of complications. Recent technological advances can improve glucose metrics and reduce hypoglycaemia frequency, yet their impact on FOH is unclear. This systematic review and meta-analysis (SRMA) aimed to synthesize the current literature to understand the impact of diabetes technologies on FOH in T1D. In this SRMA, we searched PubMed, Medline, Scopus, and Web of Science from inception up to May 21st, 2023 for studies assessing the effect of using real-time or intermittently scanned continuous glucose monitors (rtCGM or isCGM); insulin pumps (CSII); and their combinations on FOH as the primary outcome, measured using the Hypoglycaemia Fear Survey (HFS; including total, worries [HFS-W], and behaviours [HFS-B] scores), in non-pregnant adults with T1D. Data was extracted by the first and second authors. Results were pooled using a random-effects model based on study design (RCT and non-RCT), with subgroup analysis based on the type of technology, reported change in hypoglycaemia frequency, and duration of use. Risk of bias was evaluated with Cochrane and Joanna Briggs Institute tools. This study is registered with PROSPERO, CRD42021253618. A total of 51 studies (n = 8966) were included, 22 of which were RCTs. Studies on rtCGM and CSII reported lower FOH levels with ≥8 weeks of use. Studies on CSII and rtCGM combinations reported lower FOH levels after ≥13 weeks of automated insulin delivery (AID) use or 26 weeks of sensor-augmented pump (SAP) use. The meta-analysis showed an overall lower FOH with technologies, specifically for the HFS-W subscale. The RCT meta-analysis showed lower HFS-W scores with rtCGM use (standard mean difference [95%CI]: -0.14 [-0.23, -0.05], I2 = 0%) and AID (-0.17 [-0.33, -0.01], I2 = 0%). Results from non-RCT studies show that SAP users (-0.33 [-0.38, -0.27], I2 = 0%) and rtCGM users (-0.38 [-0.61, -0.14], I2 = 0%) had lower HFS-W. We found consistent, yet small to moderate, effects supporting that diabetes technologies (specifically rtCGM, SAP, and AID) may reduce hypoglycaemia-related worries in adults with T1D. Current literature, however, has limitations including discrepancies in baseline characteristics and limited, mainly descriptive, statistical analysis. Thus, future studies should assess FOH as a primary outcome, use validated surveys, and appropriate statistical analysis to evaluate the clinical impacts of technology use beyond just glucose metrics. Canadian Institutes of Health Research, Juvenile Diabetes Research Foundation Ltd.

1 March 2021 in Canadian Journal of Diabetes
Verified
Journal Article
Closed access
KWKayla Wong
Kayla Wong
MRMarie Raffray
Marie Raffray
ARAmélie Roy-Fleming
Amélie Roy-Fleming
SBSarah Blunden
Sarah Blunden
ABAnne-Sophie Brazeau
Anne-Sophie Brazeau